- Home
- Aid by Department
- Department of Science, Innovation and Technology
Department of Science, Innovation and Technology
Delivery costs of ODA eligible activities
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
Delivery costs of ODA eligible activities funded (4%) through the Global Challenges Research Fund (GCRF)
Delivery Costs for Newton Fund ODA Eligible Activities
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
Newton Fund. AHRC Staff delivery costs for ODA eligible activities
Arts and Humanities Research Council (AHRC) Delivery costs of International Science Partnerships Fund (ISPF) ODA activities
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
Operational costs occurred at Arts and Humanities Research Council (AHRC) associated with hosting and/or managing ODA International Science Partnerships Fund (ISPF) programmes
Academy of Medical Sciences - Global Policy Workshops - International Science Partnerships Fund
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
In accordance with the The Integrated Review of Security, Defence, Development and Foreign Policy, this scheme will seek to provide the UK with a strategic advantage, as it's intended that the networks/collaborations formed will be long-lasting, and will expedite the delivery of important research. The ODA funding, in particular, will facilitate the development of global science capability. However, it's hoped that all awards will contribute to tackling the global challenges, and within the scheme, there is a good chance of all priority themes being addressed. Opportunites such as this, which facilitate mobility, are powerful in terms of enhancing the UK's reputation, and contribute to the ambition for the UK to be a scientific superpower. The scheme has two funding streams: one for a selection of countries on the Development Assistance Committee (DAC) list of Official Development Assistance (ODA) recipients, to include the Least Developed Countries. The grants will help to: Deliver important science that can only be fully realised by working internationally; tackle global challenges and develop future technologies; positioning UK researchers and innovators at the heart of global solutions; and strengthen the influence and connections of the UK Research and Development (R&D) community domestically and around the world. The awards would provide up to £25,000 over one year to support collaborations between priority ODA countries and/or Least Developed Countries (LDCs) and the UK and to hold networking events aimed at addressing the priority themes identified for International Science Partnerships Fund (ISPF). The scheme would be a vehicle for researchers from across the disciplines to forge new links and generate innovative transdisciplinary research ideas. It's envisaged that these new networks will then be better positioned to compete for more substantive grants offered by future funding initiatives. This programme will be working with the British Academy, the Royal Academy of Engineering and the Royal Society to offer Networking Grants funded through the International Science Partnerships Fund (ISPF). This will allow UK-based researchers and innovators to collaborate with international partners on multidisciplinary projects. Furthermore, it will help the UK and its partners to deliver bigger, better science than one country can do alone.
Academy of Medical Sciences - Networking Awards
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
The awards would provide up to £25,000 over one year to support collaborations between priority ODA countries and/or LDCs and the UK and to hold networking events aimed at addressing the priority themes identified for ISPF. The scheme would be a vehicle for researchers from across the disciplines to forge new links and generate innovative transdisciplinary research ideas. It's envisaged that these new networks will then be better positioned to compete for more substantive grants offered by future funding initiatives.
Academy of Medical Sciences - International Career Development Programme -International Science Partnerships Fund
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
This programme builds on the Academy's extensive experience of developing programmes to support UK researchers through mentoring, tailored training in leadership, entrepreneurship and research soft skills and cohort-building Drawing on our experience of the ODA capacity building workshops piloted in 2022 and on recommendations that will emerge from the clinical research capacity building project, the career development programme will focus on identifying and fostering global best practice in supporting and connecting emerging research leaders across the health sciences sector (clinical, non-clinical, industry). Topics discussed and resources will be developed around wider leadership and entrepreneurship training, building supportive cohorts and in the second year connecting our UK cohorts with international emerging leaders for to exchange knowledge, foster collaborations and extend networks within life sciences. This activity potentially stimulate additional research impact by supporting researchers to thrive in their careers through opportunities for training, mentorship and cohort building, and also influence practice in terms of developing ways to support research careers and sharing best practice between UK and other countries. In addition, strengthen research capacity in developing countries by raising awareness and helping with the implementation of career support programmes that are important for researchers to thrive and be supported in carrying out their research, and working in partnership with organisations in partner countries, sharing best practice and forming connections between researchers in the UK and partner countries will strengthen the perceptions of UK research leadership and as a leader in the area of career development support. As with the global policy workshops, the ODA regional workshops will be developed and hosted in the ODA-eligible partner country and all outputs will be targeted towards the ODA-eligible partner country or region.
Academy of Medical Sciences - Team Science Accelerator - International Science Partnerships Fund
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
Currently termed ‘Team Science Accelerator Awards’, this funding will be available to previous recipients of the Academy's The Global Challenges Research Fund (GCRF) Networking scheme, who have a lead applicant based in one of the International Science Partnerships Fund (ISPF) ODA-priority countries, or in a Least Developed Country. The awards will enable recipients to maintain their collaborative networks and to undertake related research projects – for which they may have obtained pilot data for during their initial GCRF Networking award. As the The Global Challenges Research Fund (GCRF) Networking scheme was ODA funded and designed to address the Global Challenges, the collaborations supported via Team Science Accelerator Awards shall also be ODA-eligible in nature.
Academy of Medical Sciences - Networking Awardees and Alumni - International Science Partnerships Fund
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
This program aims to enhance global scientific collaboration by building and expanding a network of International Science Partnerships Fund (ISPF) awardees and alumni. By leveraging investments made under the Department for Business, Energy & Industrial Strategy (BEIS) through the Global Challenges Research Fund (GCRF) and Newton programs, this initiative will create valuable resources and tools on dedicated awardee and alumni portals, PILLAR and HIVE. We will facilitate online and hybrid meetings, along with in-person events, focusing on key thematic priorities such as 'Tomorrow's Talent' and 'Healthy Populations'. Through these activities, we will foster peer support, encourage new collaborations, and promote applications for further funding. Our approach is designed to align with Official Development Assistance (ODA) eligibility criteria by addressing global challenges, advancing scientific capabilities, and promoting sustainable development. By creating multi-lateral partnerships, we provide opportunities for scientific development and global issue resolution through interdisciplinary and multidisciplinary methods.
Academy of Medical Sciences - Clinical Research Pathways Policy - International Science Partnerships Fund
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
This project would work with a cohort of partners across high-, middle-, and low-income countries, to understand the pipeline for clinical researchers in each country. This could also support the global mobility of UK clinical researchers and develop the most promising talent internationally for them to collaborate with. Scoping activities to inform the development of the clinical research pathways project. This will formulate final aims,objectives and structure of the project before evidence gathering and delivery. This project will explore clinical research pathways in ODA eligible countries to understand the pipeline for clinical researchers in each country; identify key stages in the development pathway to support clinical researchers; provide ideas for further improving and target key stages in the career pathway to ensure diverse researchers continue on and contribute to excellent clinical research. This project is broad in scope and so would meet all five of the strategic objectives of the International Science Partnerships Fund (ISPF). Specifically it would develop international research partnerships to influence policy, innovation and practice change through recommendations developed by this project. It would also recommend ways for all countries to develop pathways to support clinical researchers, thus helping to build research capacity in-country. To inform the direction and focus of the clinical research pathways project, engaging with global stakeholders (particularly in the International Science Partnerships Fund (ISPF) priority countries) to identify gaps, challenges and areas for the project to take forwards.
Academy of Medical Sciences - ODA Delivery Costs - International Science Partnerships Fund
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
These are the operational costs required by the Academy of Medical Sciences to deliver International Science Partnerships Fund (ISPF). It manages Grants, Policy and Programmes activities all aimed at supporting international researchers to establish and develop collaborative partnerships with UK researchers.
Academy of Medical Sciences - International Career Development Programme -International Science Partnerships Fund (FY25/26 onwards)
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
This programme builds on the Academy's extensive experience of developing programmes to support UK researchers through mentoring, tailored training in leadership, entrepreneurship and research soft skills and cohort-building Drawing on our experience of the ODA capacity building workshops piloted in 2022 and on recommendations that will emerge from the clinical research capacity building project, the career development programme will focus on identifying and fostering global best practice in supporting and connecting emerging research leaders across the health sciences sector (clinical, non-clinical, industry). Topics discussed and resources will be developed around wider leadership and entrepreneurship training, building supportive cohorts and in the second year connecting our UK cohorts with international emerging leaders for to exchange knowledge, foster collaborations and extend networks within life sciences. This activity potentially stimulate additional research impact by supporting researchers to thrive in their careers through opportunities for training, mentorship and cohort building, and also influence practice in terms of developing ways to support research careers and sharing best practice between UK and other countries. In addition, strengthen research capacity in developing countries by raising awareness and helping with the implementation of career support programmes that are important for researchers to thrive and be supported in carrying out their research, and working in partnership with organisations in partner countries, sharing best practice and forming connections between researchers in the UK and partner countries will strengthen the perceptions of UK research leadership and as a leader in the area of career development support. As with the global policy workshops, the ODA regional workshops will be developed and hosted in the ODA-eligible partner country and all outputs will be targeted towards the ODA-eligible partner country or region.
Use of Unmanned Aerial vehicles (Medical Drones) to Support Differentiated Service Delivery Models for Elimination of HIV in Uganda
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
Context of Aims & Objectives: Fishing populations living on islands struggle to get their HIV medication and other medications, they have to travel long distances by boat to the closest health facility. Small unmanned aircraft (medical drones) are being tested in Africa for delivering medication and other medical supplies in areas where there are long distances to health centres or limited road transport. This research study hopes to compare the use of small unmanned aircraft (medical drones) to deliver medicines to people living with HIV in an island district in Uganda (Kalangala) that consists of 84 islands. We aim to see if delivering medicines by this method helps people to better manage their HIV. This will be measured by looking at the level of HIV in their blood (viral load) which gives an indication if they are taking their medicine, reacting well to their medicine. If we cannot detect HIV in their blood it is a good indication that they will suffer minimal health problems related to their HIV, and cannot pass it on to their sexual partners. We will also look to see whether people living with HIV are attending appointments for their HIV. We will also conduct research to see if people living with HIV and health workers are comfortable with using medical drones and what other medical uses, they think the drone could be helpful for. In addition, we will compare the financial costs of using drones versus boats. We will also look at different types of drones, including ones that look like the photography drones widely used by the public, to a large one that looks more like a small plane. We will also try a recyclable drone made mainly of cardboard. We will look at the carbon use of drones (which use batteries) compared to boats with petrol motors. b) Potential applications and benefits One may be tempted to ask why this study is needed. Aren't drones just transport vehicles like cars or boats? As long as they can travel the distance, why do we need to study them in a direct comparison? Drones are new and not widely used to carry medical goods. A key barrier to wider adoption has been the lack of rigorous data examining the impact of drones and their costs. The reason is that the real-life implementation of any intervention is almost always different than predicted. This has been the case for all kinds of medical and social interventions and is likely to be the case for medical drones. This study using rigorous methods, will allow us to document the real-world impact of drones beyond the estimations that people have used to justify medical drones so far. Over the last 12 months, we established a small medical drones pilot project in the Kalangala District. For three years before that, we collected data on patients' challenges getting to health centres and any problems in getting medication when they get there. Based on our observations of significant barriers to patients getting steady medicine supplies, we sought permission from the Ministry of Health and other authorities, including Civil Aviation Authority and the Ministry of Defence, to do a small medical drones project. To test to assess whether this kind of project is possible in this setting, we have managed to deliver HIV drugs to 99 people living with HIV by medical drone. Of these, we completed 12 months of delivery to 63 people using medical drones in September 2022. We have reached 5 islands and delivered to 17 peer support groups whose leaders have trained on safe drone drug delivery. It is now time for a more robust study. If this study shows that patients are comfortable receiving their medication by drone, or saves money, or helps the environment by using less petrol than boats, then we believe that medical drones could be used in many places around the world where it is difficult for people to get their medication. We would first try to extend the medical drones in East Africa and then move to other sites in Africa for further work.
VALIDATE: A vaccine R&D Network for complex intracellular pathogens
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
As the COVID-19 pandemic illustrated, vaccines play a really important part in controlling infectious diseases. If scientists work together across the world, then greater progress can be made than if they work alone. VALIDATE is a network which aims to speed up vaccine development for three groups of bugs that are difficult to design vaccines for and which cause a lot of disease and death across the world, particularly in low income countries. These diseases often do not attract lots of research and development funding, in part because they primarily affect poor people who cannot pay for expensive vaccines. VALIDATE started in 2017 and has grown from 32 founding members to now having more than 500 members around the world. Over the last five years we have supported the career development of many of our members and have also funded many small projects - some of which have led on to much bigger projects being funded by the MRC and other global funders. We now want to secure funding for the next four years so we can carry on supporting vaccine research and the careers of people working in vaccine development. Our chosen groups of bugs, which cause diseases like tuberculosis (TB), are similar in how the body responds to them. They are all very good at hiding from the immune system - which means they can stay hidden in the body and cause disease much later in life. They also need similar types of immune responses for the body to be able to get rid of them. In this network, we will do two things: 1. Provide small pots of funding for our members to perform research which will help us understand how best to develop vaccines for these difficult bugs. 2. Provide training and a supportive environment to encourage young scientists to stay working in this field. We will have a network meeting every year where our members can come and present their data and meet other scientists working in the field. We will host regular talks, which will be online to allow more people to join, particularly from lower income countries. We will offer opportunities for young scientists to have training in other laboratories, and will provide mentoring to support young scientists in their careers. We will work with schools to increase knowledge of these bugs. Overall, in this network, we aim to support vaccine development and also support the careers of people working in this field.
Scaling up One health Systems (SOS-rabies): Implementation research for rabies elimination in East Africa
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
Rabies kills tens of thousands of people every year despite effective vaccines that prevent human infection and interrupt transmission in animals having existed for over a century. Although vaccine-preventable, rabies has been neglected in low-and-middle-income countries. To change this, WHO and partners launched a global strategic plan to end human deaths from dog-mediated rabies by 2030 ('Zero by 30'). To achieve this goal access to life-saving post-exposure vaccines must be improved to ensure people bitten by rabid animals do not develop this fatal disease. However human vaccines alone will not impact rabies spread in domestic dog populations responsible for maintaining circulation. Dog vaccination must be scaled up and sustained to interrupt transmission. Gavi, the Vaccine Alliance, is poised to invest in post-exposure vaccines, with rollout in the first low-income countries from mid-2025. Gavi's investment is expected to catalyse action on dog vaccination, leveraging momentum so countries scale up strategies for rabies elimination. Tanzania has the potential to be an early-adopter country of Gavi-vaccine investment There is an urgent need for research to inform rabies vaccines rollout, both post-exposure prophylaxis and dog vaccination, to maximise their reach and impact. At this pivotal time, SOS-rabies will undertake high-impact implementation research in Tanzania aiming to reduce the rabies burden and strengthen One Health systems and capacity. Our objectives are to: Design tools to guide short and long-term planning for interventions to eliminate rabies; Develop training materials and guidance to support their scaling up; Evaluate the impact of these interventions as they are rolled out. The team will capitalise on Integrated Bite Case Management (IBCM), a One Health approach to rabies surveillance recommended by WHO. IBCM is currently being implemented as a research platform across five regions of Tanzania where rabies is endemic. Using IBCM, we will examine demand for post-exposure vaccines and synthesise learnings about current bite patient management practices, surveillance and reporting and how they can be improved. From modelling these data we will optimise supply chain design for decentralising access to post-exposure vaccines, while ensuring resilience to stockouts and feasibility of health system integration. We will develop and test tools, training and guidance to support intervention rollout, including the development of a modelling framework to forecast impacts and the use of dashboards to track impacts, including deaths, exposures and vaccine demand. Rollout policy and operational uncertainty however means that health system adaptation will be key. Employing the SOS-rabies toolbox, we will use Developmental Evaluation to support health system learning and evaluate the impacts of interventions to improve access to post-exposure vaccines and scale up mass dog vaccination. Taking a participatory and systems-based approach will facilitate learning and adaptation as this complex set of interventions is delivered across settings. Through continued engagement with stakeholders like community beneficiaries, frontline health and veterinary workers, health systems managers, national decision-makers and international policymakers, we will review data, co-design solutions to address challenges, and generate continual learning of what works. In Tanzania, we will strengthen scientific capacity and health systems; support adaptation and optimization of One Health interventions, and build political, programmatic and public support and ownership to achieve and sustain rabies freedom. Overall, our embedded collaborative research will generate transferable lessons and best practices for scaling up rabies prevention, control and surveillance, feeding into Gavi's investment on rabies, and redressing long-standing vaccine inequities.
Protecting Mothers and their Infants through Screening and Comprehensive Management of Sexually Transmitted Infections in Antenatal Care in Zimbabwe
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
Sexually transmitted infections (STIs) are extremely common. In Africa four easily curable STIs (chlamydia, gonorrhoea, trichomoniasis and syphilis) may affect almost one in four young people at any point in time. For most people these infections do not cause obvious symptoms but they can still be associated with important health consequences. In particular, STIs during pregnancy can have severe consequences for the outcome of the pregnancy. They are associated with a higher rate of stillbirth, babies dying shortly after birth (neonatal death), and with babies being born prematurely and at a lower birthweight. Despite these important public health consequences, control of STIs has not been suboptimal and no World Health Organization (WHO) STI control targets have been met. One reason is that currently only individuals with STI symptoms are treated for all the possible infections that can cause the symptom without specifically testing for which infection is causing the symptom-an approach called syndromic management. This approach was recommended because testing required expensive laboratory infrastructure which was not always possible in resource-constrained settings. Importantly, more than 80% of people with an STI do not have symptoms and are therefore not identified and treated. Newer diagnostic tests which do not require expensive infrastructure have become available in recent years but these tests are relatively expensive, and there is limited evidence on which population groups to target for testing and whether screening (i.e. offering testing systematically to defined groups whether or not they have symptoms) will result in health benefits. In previous work in Zimbabwe, we have shown that these diagnostic tests can be integrated into broader antenatal care. However critical data on whether using these tests improves outcomes for mothers and babies is missing. In this study we will conduct a trial to to assess if introducing screening for STIs in antenatal care compared to syndromic management results in improved outcomes for the mothers and their babies. Our study will be conducted in antenatal care clinics in Zimbabwe. We will enrol approximately 8200 pregnant women into the study. Pregnant women will be assigned by chance (randomised) to either receive standard care, where they will be treated for an STI only if they have symptoms, or to receive a test for an STI whether or not they hae symptoms, followed by treatment based on the result of that test. For each pregnancy we will collect data on important outcomes including stillbirth, prematurity and birth weight to assess if STI testing improves pregnancy outcomes. We will also collect data on the cost of using diagnostic tests in the antenatal setting and conduct a thorough evaluation of the operational and structural factors required for Ministries of Health to adopt STI testing as part of antenatal care more widely. Throughout the study we will work directly with communities to ensure the services we develop are appropriate for their needs and tackle barriers to seeking care for STIs such as stigma. We will develop a detailed plan to facilitate uptake of our study findings into local, regional and global policy, working with the Ministry of Health, WHO and other key stakeholders such as the International Union against STIs. We will also advocate with Industry for reductions in costs of tests. If successful our study will transform care for pregnant women and improve outcomes for their babies worldwide.
Neonatal early warning score for hypothermia evaluation and treatment (NEWS-HEAT): a cluster randomised controlled trial with internal pilot phase
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
Globally, 15 million babies are born prematurely every year. One million babies die before their 5th birthday, many due to complications of prematurity. In Kenya, the neonatal mortality rate (death in the first month of life) is 20 per 1000 live births. This is 8 times higher than the UK and much higher than the Sustainable Development Goals' target of less than 12 per 1000 live births by 2030. Babies born premature (before 37 weeks) or low birth weight (LBW; less than 2.5kg) often become cold (hypothermia) after birth as they cannot keep themselves warm. In Kenya, around half of babies who are admitted for neonatal care have hypothermia on admission. Cold babies are more likely to die or have other life-threatening conditions. Keeping babies warm in the labour ward and during transfer for further care is vital. In 2018, our multidisciplinary UK-Kenya collaboration started a research programme, to investigate if an early warning score could help identify preterm babies who are sicker, where action needs to be taken quickly. An early warning score (EWS) is a simple, paper document which uses a traffic-light colour-coded system to record babies' vital signs, like temperature, offering a simple way for health professionals to identify babies who need additional care. This prompts them to act, monitor how the baby responded and decide if further action is needed. We found that using EWS is possible and health professionals, parents and policy-makers support its use. Labour wards in Kenya are often under-resourced and staff are not fully trained in newborn care. Although early essential newborn care (EENC) is standard care it is not well implemented. Without a clear process of how to record temperature, put in measures to keep babies warm, and monitor their progress, babies often get cold. NEWS-HEAT is a care bundle, which includes evidence-based actions to keep babies warm and prevent hypothermia. It is a paper chart with an EWS and decision-aid to trigger action and monitor babies. NEWS-HEAT could help staff and parents note when babies are cold, act to warm them, and continue to monitor to ensure babies stay warm. We will test if NEWS-HEAT will reduce the number of babies who are cold. We will randomly allocate 28 hospitals to use EENC, with or without the NEWS-HEAT bundle. Each hospital will take part for 8 months. In all hospitals, before any intervention takes place, we will collect baseline data on all preterm/LBW babies. Then, all hospitals will receive training in EENC, using a train-the-trainer approach. Finally, staff in half of hospitals will receive training on and then implement the NEWS-HEAT care bundle. The other half of hospitals will continue to use EENC alone. We will measure which group of hospitals has fewer babies who became cold by recording the temperatures at the point of admission for newborn care. We will also check other important outcomes including how many babies die within 1 week of birth. We anticipate 11,200 babies being involved. We will also conduct a process evaluation to check if NEWS-HEAT is implemented properly and staff views of it. Our partners include the Ministry of Health and a parent support group. NEWS-HEAT has the potential to reduce hypothermia and save babies' lives in Kenya and other low and middle income countries, contributing to reaching the Sustainable Development Goals.
Africa Research Excellence Fund (AREF)
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
The Research Development Fellowships (RDF) give talented post-doctoral researchers funding for fellowship placements to develop their own research ideas, and capacity building support to help them on the journey to research independence. The continued benefit of being part of the active and supportive AREF alumni network. The Fellowship provides the fellows with an experienced mentor, who is focused solely on the fellows professional and career development, and not directly involved in their research project. These mentors are independent of both host and home institution, and therefore, are an additional avenue for independent advice, guidance and support for the fellows. This includes: • 3 to 9-month placement at a leading research institution in Africa, the UK or the rest of Europe. • Professional skills development including grant writing, mentorship, building networks and developing new collaborations. • Seed funding competition will award up to £50K for a pilot project lasting up to one year after the completion of their research development fellowship. The fellow will have the opportunity to win seed funding to develop their own research group at the end of the fellowship period. AREF will deliver a series of Grant writing workshops consisting of an intensive two weeks of workshops, with a five-week gap between weeks to prepare draft proposals which are peer reviewed by AREF facilitators and fellow participants. At the end of the programme, participants will have completed a significant piece of writing and a professional development plan.
SAMRC-run UK South Africa call on climate, one health and zoonosis
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
Six research projects have been supported focusing on emerging, re-emerging, and endemic zoonotic, vector-borne and other diseases and antimicrobial resistance that are linked to climate change and the environment. Projects will looks at the transmission dynamics of relevant diseases across various environmental settings and will look at methods for early detection and surveillance. This activity is led and delivered by SAMRC, who will issue research grants that are led by South African investigators with UK-based co-investigators and the opportunity to involve coinvestigators across Africa. Working in this way will promote equitable partnerships within the projects and ensure that the research funding delivers on the priorities of the primary beneficiary country involved (South Africa) as well as the possibility to deliver on the priorities of other beneficiary countries across Africa.
SAMRC-run UK South Africa call on Co-Infections with Non-Communicable Diseases
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
Three research projects have been supported focusing on the interaction of infectious diseases such as HIV and Tuberculosis with noncommunicable diseases such as cardiovascular diseases and respiratory diseases. Projects will seek to understand how diseases interact and will develop new insights into the patterns and determinants of multimorbidity in South Africa. This activity is led and delivered by SAMRC, who will issue research grants that are led by South African investigators with UK-based co-investigators and the opportunity to involve coinvestigators across Africa. Working in this way will promote equitable partnerships within the projects and ensure that the research funding delivers on the priorities of the primary beneficiary country involved (South Africa) as well as the possibility to deliver on the priorities of other beneficiary countries across Africa.
SAMRC-run UK South Africa call on Non-Communicable Diseases including Mental Health
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
Five research projects have been supported to focus on NCDs and mental health. Projects will look to improve our understanding of disease mechanisms, presentation and progression and inform innovative prevention and treatment strategies. This activity is led and delivered by SAMRC, who will issue research grants that are led by South African investigators with UK-based co-investigators and the opportunity to involve coinvestigators across Africa. Working in this way will promote equitable partnerships within the projects and ensure that the research funding delivers on the priorities of the primary beneficiary country involved (South Africa) as well as the possibility to deliver on the priorities of other beneficiary countries across Africa.
Advanced filters
To search for Programmes in a specific time period, please enter the start and end dates.